Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Determinants of steady-state torasemide pharmacokinetics: impact of pharmacogenetic factors, gender and angiotensin II receptor blockers.

Clinical pharmacokinetics - 1 Jan 2008

Werner Dierk, Werner Ulrike, Meybaum Annett, Schmidt Boris, Umbreen Sumaira, Grosch Anton, Lestin Heiko G, Graf Bernhard, Zolk Oliver, Fromm Martin F

Abstract excerpt

BACKGROUND: Torasemide is frequently used for the treatment of hypertension and heart failure. However, the determinants of torasemide pharmacokinetics in patients during steady-state conditions are largely unknown. We therefore explored the impact of genetic polymorphisms of cytochrome P450 (CYP...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiotensin II Type 1 Receptor Blockers
Share to Antihypertensive Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Calibration

Share to Cytochrome P-450 CYP2C9

Share to Drug Interactions

Share to Half-Life

Share to Liver-Specific Organic Anion Transporter 1

Share to Organic Anion Transporters

Source

Identifiers

PMID: 18399713
DOI: 10.2165/00003088-200847050-00003

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-18399713-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Determinants of steady-state torasemide pharmacokinetics: impact of pharmacogenetic factors, gender and angiotensin II receptor blockers.PMID 18399713Read ↗

CYP2C9 polymorphisms and the interindividual variability in pharmacokinetics and pharmacodynamics of the loop diuretic drug torsemide.Semantic proximity Read ↗

The impact of pharmacogenetics of metabolic enzymes and transporters on the pharmacokinetics of telmisartan in healthy volunteers.Semantic proximity Read ↗

Repaglinide-irbesartan drug interaction: effects of SLCO1B1 polymorphism on repaglinide pharmacokinetics and pharmacodynamics in Chinese population.Semantic proximity Read ↗

Effect of organic anion-transporting polypeptide 1B1 (OATP1B1) polymorphism on the single- and multiple-dose pharmacokinetics of enalapril in healthy Chinese adult men.Semantic proximity Read ↗

Stereoselective interaction of tolvaptan with amiodarone under racemic metabolic impact by CYP3A5 genotypes in heart failure patients.Semantic proximity Read ↗

Pharmacokinetics of tolterodine in Japanese and Koreans: physiological and stochastic assessment of ethnic differences.Semantic proximity Read ↗

UMOD Genotype-Blinded Trial of Ambulatory Blood Pressure Response to Torasemide.Semantic proximity Read ↗

Insights into Intestinal P-glycoprotein Function using Talinolol: A PBPK Modeling ApproachSemantic proximity Read ↗

Pharmacogenomics of celiprolol - evidence for a role of P-glycoprotein and organic anion transporting polypeptide 1A2 in celiprolol pharmacokinetics.Semantic proximity Read ↗

Losartan and E3174 pharmacokinetics in cytochrome P450 2C9*1/*1, *1/*2, and *1/*3 individuals.Semantic proximity Read ↗

Polymorphism of ORM1 is associated with the pharmacokinetics of telmisartan.Semantic proximity Read ↗

UGT1A3 and Sex Are Major Determinants of Telmisartan Pharmacokinetics-A Comprehensive Pharmacogenomic Study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.